A Letter
代表メッセージ
A letter from the chairman.
Addressed to
To every woman who opens this letter.

The question that began it all
"The world does not lack cosmetics, skincare, or beauty companies. Then why, after all, does Toyo Bijin exist?"
Toyo Bijin Holdings
Toyo Bijin Holdings — Office of the Chairman
Kyoto · 2018
To every woman who opens this letter—
In all the years I have led this company, I have asked myself one question — the world does not lack cosmetics, skincare, or beauty companies. Then why, after all, does Toyo Bijin exist?
Only when I looked back did I realize: we needed a century to find the answer.
Over the past century, the outer beauty of women has been depicted, sculpted, and commodified again and again — from the runways of Paris to the glass counters of Ginza, from countless polished commercials to the recommendations of social media. Yet one domain has been forgotten from beginning to end — the deepest, most private inner beauty that belongs to a woman, and to her alone.
This is a blind spot. Intimate care requires a seven-to-ten-year research cycle; daily skincare is itself a restraint of "ten years per formula" — yet the patience of conventional beauty capital rarely lasts beyond eighteen months. Outer and inner beauty were meant to complete and illuminate each other, granting a woman a life truly whole. What this industry calls for is not desire, but patience. So we chose a third path — where the most patient research meets the most enduring capital. This is our dual-engine strategy.
What I can promise every woman is this: we will take a century to do one thing — to ensure that, at thirty, at forty, at fifty, at sixty, and for the whole of your life, you remain the woman this world — and the heart of the one who loves you most — yearns for and reaches toward.
This is the full extent of what I, as the representative of this Group, can promise you.
Yours sincerely
Yours sincerely
鷹野 玄太(Takano Genta)
Representative Director & Chairman
Toyo Bijin Holdings
Seal · 印

Kyoto Life Sciences Institute · 2014
Discover our
dual-engine strategy
Life Sciences × Strategic Capital
See the dual-engine business model→